{"id":910354,"date":"2025-11-14T16:47:12","date_gmt":"2025-11-14T21:47:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/"},"modified":"2025-11-14T16:47:12","modified_gmt":"2025-11-14T21:47:12","slug":"neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/","title":{"rendered":"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CALABASAS, Calif., Nov.  14, 2025  (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NTHI) (\u201cNeOnc\u201d or the \u201cCompany\u201d), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones.<\/p>\n<p>\n        <strong>Third Quarter &amp; Recent Corporate Highlights<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Middle East \u2013 NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42\u2019s IROS, and completing ADGM incorporation. The company also progressed a $50\u202fmillion strategic partnership with Quazar Investment, strengthening Abu Dhabi\u2013US collaboration in brain cancer treatment.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Non-Dilutive NIH Funding \u2013 Awarded $2.5 million in STTR grants to advance NEO212 for gliomas and leukemia, underscoring strong scientific validation and external funding support.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Technology Expansion \u2013 Executed an agreement to acquire an Advanced AI and 3D Bioprinting IP.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Media &amp; Market Visibility\n<ul type=\"circle\">\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Featured on Fox Business, Bloomberg Television<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Interviewed on Yahoo Finance\u2019s Trader Talk podcast discussing AI and biotech\u2019s role in brain cancer treatment.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Entered a 12-part national TV and media campaign with New to The Street, including commercials, earned media, and billboards.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Interviewed live by Kenny Polcari (@Floorstocks).<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Index Inclusion \u2013 Joined the Russell Microcap\u00ae Index, broadening exposure to institutional investors.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Strong IP Protection \u2013 Global patent portfolio spans all major pharmaceutical markets, covering the company\u2019s core CNS oncology assets.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Executive Leadership \u2013 Appointed Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Scientific Leadership &#8211; Appointed leading neuro-oncologists Dr. David M. Ashley (Duke University), Dr. Alexandra M. Miller (NYU Langone Health), and Dr. Henry S. Friedman to its Scientific Advisory Board<\/li>\n<\/ul>\n<p>\n        <strong>Clinical Pipeline Progress<\/strong>\n      <\/p>\n<p>NEO100-01 \u2013 Intranasal therapy for malignant recurrent WHO Grade 3 \/4 IDH1 Astrocytoma<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Announced Phase 2a clinical results for NEO100 in recurrent brain cancer, showing a 21% response rate vs. &lt;8% historical average<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">44% of patients achieved six-month progression-free survival vs. 21-31% in historical datasets<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">33% remained alive \u226518 months after initiation of NEO100, demonstrating long term survival<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">No significant toxicity was reported<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Dr. Henry Friedman of Duke University emphasized the implications of these findings, stating, \u201cThe results from NEO100 signify a potential paradigm shift in the treatment of recurrent IDH1-mutant gliomas.\u201d<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">The findings were presented to the investment community during NeOnc\u2019s November 12, 2025, investor conference call, which is available for replay at: <a href=\"https:\/\/www.webcaster5.com\/Webcast\/Page\/3151\/53234\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.webcaster5.com\/Webcast\/Page\/3151\/53234<\/a>.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Full Phase 2a enrollment completed<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Top-line data readout anticipated in May 2026<\/li>\n<\/ul>\n<p>NEO212 \u2013 Bio-conjugated therapy for primary and metastatic brain tumors<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:9pt\">FDA authorization to proceed with Phase II Clinical Trial of NEO212 \u2013 a first-in-class oral chemical conjugated chemotherapy candidate for brain cancer<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Final patient cohort in Phase I on track to complete dosing in 2025.<\/li>\n<\/ul>\n<p>NEO100-3 \u2013 Pediatric brain tumor trial initiated with patient recruitment underway.<\/p>\n<p>\n        <strong>Financial Results for Q3 2025<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:9pt\">G&amp;A expenses: $903k vs. $244k in Q3 2024, reflecting expanded marketing, rent, travel, and Middle East partnership-related costs.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">R&amp;D expenses: $715K vs. $957k in Q3 2024, driven by active management of NEO100 trial sites, recruitment for NEO212, initiation of NEO100-3, and overall patient recruitment activity.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Net loss: $8.6 million or $0.45 per diluted share, compared to $2.2 million or $0.12 per diluted share in Q3 2024, primarily due to increased general and administrative expenses, as well as stock-based compensation expenses.<\/li>\n<\/ul>\n<p>Amir Heshmatpour, Executive Chairman, President &amp; CEO of NeOnc Technologies Holdings, Inc., commented:<\/p>\n<p>\u201cQ3 2025 was a defining quarter for NeOnc\u2014one that firmly positions us at the forefront of innovation in CNS oncology. We delivered exceptional clinical progress, highlighted by highly encouraging Phase 2a data from our NEO100 program that signal a potential paradigm shift for patients battling recurrent high-grade gliomas. We also achieved a major regulatory milestone with FDA clearance to advance our second asset, NEO212, into Phase 2 trials, further strengthening the depth and momentum of our pipeline.<\/p>\n<p>Strategically and financially, we reinforced the foundation for long-term global growth. We secured meaningful support from the NIH and finalized a landmark $50 million commitment through our NuroMENA subsidiary\u2014an agreement that accelerates our expansion across the Middle East and positions NeOnc as a clinical and scientific partner of choice in the region. This progress is further strengthened by the appointment of H.H. Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman of NuroMENA, whose leadership and vision bring extraordinary strategic value and elevate our international standing.<\/p>\n<p>With a fortified leadership team, heightened market visibility, and multiple significant clinical catalysts ahead, NeOnc enters the next stage of execution with confidence. We are advancing life-changing therapies for patients who urgently need new options, while driving meaningful value creation for our\u00a0shareholders.\u201d<\/p>\n<p>\n        <strong>Upcoming Catalysts<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Q4 2025 \u2013 Completion of NEO212 Phase I final cohort dosing.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">May 2026 \u2013 NEO100-01 top-line data readout.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:9pt\">Near-term \u2013 Closing and funding of the Quazar Investment of $50 million.<\/li>\n<\/ul>\n<p>\n        <strong>ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.<\/strong><br \/>\n        <br \/>NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company\u2019s NEO\u2122 drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc\u2019s NEO100\u2122 and NEO212\u2122 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.<\/p>\n<p>For more about NeOnc and its pioneering technology, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NXBEPergOX1FTWv0pfuin1rdPssKwH5vmYtuFbgqs5XpF7AK25KVvUpm1zsQrahmxolSpAU1fbYUrpQEBt_AQYsHjd6ohKkVe2nvEDA7v4CyzYeO6k7F54lf_x1CH0IUg5RjYPYxrAqp3ygaEAp9qsbhhRNIoqT_RQBHrECvMkRNSkmG6FBb_IiJhWPkBo8zkvOj04BmOmKLrUX_pDbiJFQ_sYFaLMJWRValK4cBi2I1KrIfyd8tvgys6ktheccxAdGuVbqOe8s2gs7m2KrtnPu-sScQXlTD4AZVfT5BF3fvbRh8nxGg3tBbqCQj_p8pvuGUW_niKWfg9QKWsD0wrUfw48VGF3eR80l75jEkLU3e2vqmZmJHOHPZP7YIGFNhvW5rRxCqjxDqA-kQDZY7O7s2k-YapFNstorpY8G66o4IlmiyLGyDk3J6e54nMufWN-XD2Wux373qlL337pH_9QPkpmquYKjeTC5x0qX65ErT2WcJMSzQ20a1g9EjwGEViENtpeuVKzDlssegCPcdSXsWKGvizDs73lQwxuw-jSRnIiUpcDdEJUzD52O2rnkzy6hG9scoalMQeHyOMLl-GG0uee0dEkEAGdys81Vrm49YG_w_20c0DdpSZNfIRkmvvho_DnEAmrOetgfIfVL0WvBcFqYCQCu5ZViM6rBKrSX_8UV0Pl3IDhxvot97SH30sZadkq7QYLxBLewyU0kKQHDgpo8tSA49J-KJf7hpqHHDffoPa320IHNal4fSq1IW1WN3MD-Xu7Y_0g7iVYMquz-TGRIUeggIDLVo95KEnr5g6qP1D7xy0r6-1mcgpf68r14M-RycWT_s5tDfz2nbIMHqRwtQvD7yc-iXsqEgKA-hjychtLFeJbj_DqlrKV0rVuq7AvKVjnZNRIE007aHaeLlt3lCSSIhh9NfDGifV3tsCua55qw-whYwBybgi58Bu5OWiZ10C-8jKgbPz1qDc2FL58761rk93i21JaS2acxlLGuIFr5Vunqc5dPNA7kI\" rel=\"nofollow\" target=\"_blank\">neonc.com<\/a>.<\/p>\n<p>\n        <strong>Important Cautions Regarding Forward Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cevaluating,\u201d or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.<\/p>\n<p>Examples of forward-looking statements include, among others, statements regarding the potential positive effects of NEO100. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. The \u201cRisk Factors\u201d section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.<\/p>\n<p>\u201cNEO100\u201d and NEO \u201c212\u201d are registered trademarks of NeOnc Technologies Holdings, Inc.<\/p>\n<p>Company Contact:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3SSa4k3HBKrKdhjlvDH4iLCuyedD-cDlF32dV-RG6JFf9KwKQBIrKzakqhqDGkNOBwA9kV_dHd4ltg6Lz0pP0g==\" rel=\"nofollow\" target=\"_blank\">info@neonc.com<\/a>\u00a0<\/p>\n<p>Investor Contact:<br \/>James Carbonara<br \/>Hayden IR<br \/>(646)-755-7412<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9GeapfuK0_ZtI0U938_d_iTe_YjRAp1mm1An6WjoAVDs7oI7o4ApSJJ2wsmctIRuUXwO02MS7Bjzyp-i9s2FP3faGdIQ7l_veo81GUtXxs8=\" rel=\"nofollow\" target=\"_blank\">James@haydenir.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDhjZDg2ZGEtN2JkMC00OTQ0LWEyZjYtOTM0Zjg2YjgyOGQxLTEyNjgzODctMjAyNS0xMS0xNC1lbg==\/tiny\/NeOnc-Technologies-Holdings-In.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NTHI) (\u201cNeOnc\u201d or the \u201cCompany\u201d), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Third Quarter &amp; Recent Corporate Highlights Middle East \u2013 NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42\u2019s IROS, and completing ADGM incorporation. The company also progressed a $50\u202fmillion strategic partnership with Quazar Investment, strengthening Abu Dhabi\u2013US collaboration in brain cancer treatment. Non-Dilutive NIH Funding \u2013 Awarded $2.5 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-910354","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NTHI) (\u201cNeOnc\u201d or the \u201cCompany\u201d), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Third Quarter &amp; Recent Corporate Highlights Middle East \u2013 NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42\u2019s IROS, and completing ADGM incorporation. The company also progressed a $50\u202fmillion strategic partnership with Quazar Investment, strengthening Abu Dhabi\u2013US collaboration in brain cancer treatment. Non-Dilutive NIH Funding \u2013 Awarded $2.5 &hellip; Continue reading &quot;NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T21:47:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update\",\"datePublished\":\"2025-11-14T21:47:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/\"},\"wordCount\":1200,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/\",\"name\":\"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=\",\"datePublished\":\"2025-11-14T21:47:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/","og_locale":"en_US","og_type":"article","og_title":"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update - Market Newsdesk","og_description":"CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NTHI) (\u201cNeOnc\u201d or the \u201cCompany\u201d), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Third Quarter &amp; Recent Corporate Highlights Middle East \u2013 NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42\u2019s IROS, and completing ADGM incorporation. The company also progressed a $50\u202fmillion strategic partnership with Quazar Investment, strengthening Abu Dhabi\u2013US collaboration in brain cancer treatment. Non-Dilutive NIH Funding \u2013 Awarded $2.5 &hellip; Continue reading \"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-14T21:47:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update","datePublished":"2025-11-14T21:47:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/"},"wordCount":1200,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/","name":"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=","datePublished":"2025-11-14T21:47:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU3NjM1NSM3MjY1Nzc4IzIyNTY4Mzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-holdings-reports-third-quarter-2025-results-and-provides-operational-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=910354"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910354\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=910354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=910354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=910354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}